Literature DB >> 33546417

Inflammation-Related Changes in Mood Disorders and the Immunomodulatory Role of Lithium.

Kosma Sakrajda1, Aleksandra Szczepankiewicz1.   

Abstract

Mood disorders are chronic, recurrent diseases characterized by changes in mood and emotions. The most common are major depressive disorder (MDD) and bipolar disorder (BD). Molecular biology studies have indicated an involvement of the immune system in the pathogenesis of mood disorders, and showed their correlation with altered levels of inflammatory markers and energy metabolism. Previous reports, including meta-analyses, also suggested the role of microglia activation in the M1 polarized macrophages, reflecting the pro-inflammatory phenotype. Lithium is an effective mood stabilizer used to treat both manic and depressive episodes in bipolar disorder, and as an augmentation of the antidepressant treatment of depression with a multidimensional mode of action. This review aims to summarize the molecular studies regarding inflammation, microglia activation and energy metabolism changes in mood disorders. We also aimed to outline the impact of lithium on these changes and discuss its immunomodulatory effect in mood disorders.

Entities:  

Keywords:  biomarkers; inflammation; lithium treatment; mood disorders

Mesh：

Substances：

Year:  2021        PMID： 33546417      PMCID： PMC7913492          DOI： 10.3390/ijms22041532

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN： 1422-0067            Impact factor:   5.923


  115 in total

1.  Microglial NLRP3 inflammasome activation mediates IL-1β-related inflammation in prefrontal cortex of depressive rats.

Authors:  Ying Pan; Xu-Yang Chen; Qing-Yu Zhang; Ling-Dong Kong
Journal:  Brain Behav Immun       Date:  2014-05-22       Impact factor: 7.217

Review 2.  Microglial M1/M2 polarization and metabolic states.

Authors:  Ruben Orihuela; Christopher A McPherson; Gaylia Jean Harry
Journal:  Br J Pharmacol       Date:  2015-05-11       Impact factor: 8.739

3.  Efficacy of folic acid as an adjunct to lithium therapy on manic-like behaviors, oxidative stress and inflammatory parameters in an animal model of mania.

Authors:  Samira Menegas; Gustavo C Dal-Pont; José H Cararo; Roger B Varela; Jorge M Aguiar-Geraldo; Taise Possamai-Della; Monica L Andersen; João Quevedo; Samira S Valvassori
Journal:  Metab Brain Dis       Date:  2019-12-15       Impact factor: 3.584

4.  Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies.

Authors:  Amirhossein Modabbernia; Shervin Taslimi; Elisa Brietzke; Mandana Ashrafi
Journal:  Biol Psychiatry       Date:  2013-02-16       Impact factor: 13.382

Review 5.  Is bipolar disorder an inflammatory condition? The relevance of microglial activation.

Authors:  Laura Stertz; Pedro V S Magalhães; Flávio Kapczinski
Journal:  Curr Opin Psychiatry       Date:  2013-01       Impact factor: 4.741

6.  Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity.

Authors:  Christopher J Yuskaitis; Richard S Jope
Journal:  Cell Signal       Date:  2008-10-29       Impact factor: 4.315

Review 7.  Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms.

Authors:  Tamás Rőszer
Journal:  Mediators Inflamm       Date:  2015-05-18       Impact factor: 4.711

8.  Lithium is able to minimize olanzapine oxidative-inflammatory induction on macrophage cells.

Authors:  Marcelo Soares Fernandes; Fernanda Barbisan; Verônica Farina Azzolin; Pedro Antônio Schmidt do Prado-Lima; Cibele Ferreira Teixeira; Ivo Emílio da Cruz Jung; Charles Elias Assmann; Rogerio Tomasi Riffel; Marta Maria Medeiros Frescura Duarte; Ednea Maia Aguiar-Ribeiro; Ivana Beatrice Mânica da Cruz
Journal:  PLoS One       Date:  2019-01-29       Impact factor: 3.240

9.  Immunophenotypes associated with bipolar disorder and lithium treatment.

Authors:  Tai-Na Wu; Chau-Shoun Lee; Bo-Jian Wu; Hsiao-Ju Sun; Chieh-Hsing Chang; Chun-Ying Chen; Chih-Ken Chen; Lawrence Shih-Hsin Wu; Andrew Tai-Ann Cheng
Journal:  Sci Rep       Date:  2019-11-25       Impact factor: 4.379

10.  Inflammasome signaling affects anxiety- and depressive-like behavior and gut microbiome composition.

Authors:  M-L Wong; A Inserra; M D Lewis; C A Mastronardi; L Leong; J Choo; S Kentish; P Xie; M Morrison; S L Wesselingh; G B Rogers; J Licinio
Journal:  Mol Psychiatry       Date:  2016-04-19       Impact factor: 15.992
View more
  4 in total

Review 1.  Blood-Brain Barrier Dysfunction in the Pathogenesis of Major Depressive Disorder.

Authors:  Shusheng Wu; Yuye Yin; Longfei Du
Journal:  Cell Mol Neurobiol       Date:  2021-10-12       Impact factor: 4.231

2.  Lithium produces bi-directionally regulation of mood disturbance, acts synergistically with anti-depressive/-manic agents, and did not deteriorate the cognitive impairment in murine model of bipolar disorder.

Authors:  Chuanjun Zhuo; Chunhua Zhou; Hongjun Tian; Qianchen Li; Jiayue Chen; Lei Yang; Qiuyu Zhang; Ranli Li; Xiaoyan Ma; Ziyao Cai; Guangdong Chen; Yong Xu; Xueqin Song
Journal:  Transl Psychiatry       Date:  2022-09-02       Impact factor: 7.989

3.  Serum Levels and in vitro CX3CL1 (Fractalkine), CXCL8, and IL-10 Synthesis in Phytohemaglutinin-Stimulated and Non-stimulated Peripheral Blood Mononuclear Cells in Subjects With Schizophrenia.

Authors:  Jaśmina Arabska; Adam Wysokiński; Ewa Brzezińska-Błaszczyk; Elżbieta Kozłowska
Journal:  Front Psychiatry       Date:  2022-06-17       Impact factor: 5.435

4.  Lithium bidirectionally regulates depression- and mania-related brain functional alterations without worsening cognitive function in patients with bipolar disorder.

Authors:  Chuanjun Zhuo; Guangdong Chen; Jiayue Chen; Hongjun Tian; Xiaoyan Ma; Qianchen Li; Lei Yang; Qiuyu Zhang; Ranli Li; Xueqin Song; Chunhai Huang
Journal:  Front Psychiatry       Date:  2022-09-15       Impact factor: 5.435
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.